We are live on ! Find out more
GWPH

GW Pharmaceuticals Plc American Depositary Shares
GWPH

Delisted

GWPH was delisted on the 4th of May, 2021.

318 hedge funds and large institutions have $4.35B invested in GW Pharmaceuticals Plc American Depositary Shares in 2019 Q2 according to their latest regulatory filings, with 50 funds opening new positions, 107 increasing their positions, 78 reducing their positions, and 47 closing their positions.

New
Increased
Maintained
Reduced
Closed

37% more repeat investments, than reductions

Existing positions increased: 107 | Existing positions reduced: 78

10% more capital invested

Capital invested by funds: $3.94B → $4.35B (+$412M)

6% more first-time investments, than exits

New positions opened: 50 | Existing positions closed: 47

1% less funds holding

Funds holding: 320318 (-2)

26% less call options, than puts

Call options by funds: $134M | Put options by funds: $181M

29% less funds holding in top 10

Funds holding in top 10: 75 (-2)

Holders
318
Holders Change
-2
Holders Change %
-0.63%
% of All Funds
6.91%
Holding in Top 10
5
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-28.57%
% of All Funds
0.11%
New
50
Increased
107
Reduced
78
Closed
47
Calls
$134M
Puts
$181M
Net Calls
-$46.4M
Net Calls Change
+$22.1M
Name Holding Trade Value Shares
Change
Change in
Stake
ED
176
Exane Derivatives
France
$290K +$262K +1,515 +902%
11A
177
10-15 Associates
New York
$288K +$5.19K +30 +2%
FRM
178
Fox Run Management
Connecticut
$279K -$101K -586 -27%
SCM
179
Silvant Capital Management
Georgia
$278K +$279K +1,611 New
Comerica Bank
180
Comerica Bank
Texas
$267K -$4.32K -25 -2%
HF
181
HRT Financial
New York
$261K +$262K +1,517 New
BOPW
182
Brandywine Oak Private Wealth
Pennsylvania
$253K +$6.05K +35 +2%
SPC
183
Sigma Planning Corp
Michigan
$247K +$1.38K +8 +0.6%
OC
184
Oppenheimer & Co
New York
$234K +$3.11K +18 +1%
CA
185
Continuum Advisory
Idaho
$233K -$8.65K -50 -4%
PA
186
Pinnacle Associates
New York
$232K -$35.3K -204 -13%
DBT
187
Dubuque Bank & Trust
Iowa
$230K +$87.9K +508 +62%
DTL
188
Dynamic Technology Lab
Singapore
$228K +$229K +1,324 New
APA
189
American Portfolios Advisors
New York
$228K +$131K +757 +134%
SF
190
Synovus Financial
Georgia
$225K
BS
191
Boenning & Scattergood
Pennsylvania
$219K +$3.46K +20 +2%
LFAS
192
Level Four Advisory Services
Texas
$218K +$10.6K +61 +5%
RIA
193
Realta Investment Advisors
Delaware
$218K +$118K +683 +120%
AAP
194
Aristotle Atlantic Partners
Florida
$215K +$216K +1,250 New
BCM
195
Brookstone Capital Management
Illinois
$210K +$211K +1,220 New
UCFA
196
United Capital Financial Advisors
Texas
$208K +$208K +1,205 New
BRWA
197
B. Riley Wealth Advisors
Florida
$207K -$45.1K -261 -18%
WS
198
Wedbush Securities
California
$203K -$51.9K -300 -20%
GCM
199
Gables Capital Management
Florida
$198K
FHA
200
Flagship Harbor Advisors
Massachusetts
$195K +$5.54K +32 +3%

GWPH Hedge Fund Activity: Q2 2019 in Review

318 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in GW Pharmaceuticals Plc American Depositary Shares (GWPH) for Q2 2019, worth a combined $4.35B — up 10% from $3.94B a quarter earlier.

Buyers outnumbered sellers: 50 funds opened new GWPH positions and 47 closed out — a net gain of 3 holders — while 107 added to existing stakes and 78 trimmed.

The largest buyer was Point72 Asset Management, adding an estimated $110M. The largest seller was Scopia Capital Management, exiting entirely with an estimated $126M sold.

  • 318 institutional investors held GW Pharmaceuticals Plc American Depositary Shares (GWPH) as of Q2 2019, down from 320 in Q1 2019.
  • Funds reported $4.35B of GW Pharmaceuticals Plc American Depositary Shares stock for Q2 2019, up 10% quarter-over-quarter.
  • 50 funds opened new GW Pharmaceuticals Plc American Depositary Shares positions in Q2 2019 and 47 closed out, a net change of +3 holders.
  • The largest GW Pharmaceuticals Plc American Depositary Shares buyer in Q2 2019 was Point72 Asset Management, an estimated $110M added.
  • The largest GW Pharmaceuticals Plc American Depositary Shares seller in Q2 2019 was Scopia Capital Management, an estimated $126M sold.

Based on aggregated 13F filings for Q2 2019.